OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Ischemic Heart Disease in Older People
Submission Deadline: May 30, 2021 (Open) Submit Now
Clara Bonanad, MD, PhD
Servicio de Cardiología, Hospital Clínico Universitario, INCLIVA, Universitat de Valencia, Valencia, Spain
Research Interests: Myocardial infarction; echocardiography; pacemakers; cardiac imaging; diabetes; cardiovascular; heart failure; cardiology; coronary artery disease; acute heart failure; acute coronary syndrome
About this Topic
Ischemic heart disease in the elderly patient has a series of peculiarities: increased morbidity and mortality, underdiagnosis, under-treatment, procedural complications, pharmacological side-effects, etc . However, specific recommendations in this context are limited to the use of drug-eluting stents (IA), radial access (IB), and assessment of frailty, comorbidities, and side effects (IC) [2, 3]. In other words, there is a need to find specific evidence that justifies further research in this field.
Urgent reperfusion is the established standard of care in ST segment elevation myocardial infarction (STEMI) even in the elderly . However, in the acute coronary syndrome (ACS) without ST segment elevation setting there is a lack of solid evidence on whether an invasive or a conservative strategy is indicated. A recent meta-analysis found that those ≥65 years treated invasively have a lower rate of subsequent revascularization but without differences in mortality, infarction or stroke . Moreover, randomized trials addressing this issue yield controversial results . Influence of comorbidities and frailty may be crucial in determining the appropriate strategy.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (email@example.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!